DreaMed Diabetes

About:

DreaMed Diabetes offers AI solutions and personalized support for optimized insulin therapy.

Website: https://dreamed-diabetes.com/

Twitter/X: DreaMedDiabetes

Top Investors: Medtronic, eHealth Ventures, Millhouse, The Leona M. and Harry B. Helmsley Charitable Trust

Description:

DreaMed Diabetes is a medical device, SaaS company providing personalized diabetes treatment optimization solutions. The company was established in 2014, commercializing the first artificial pancreas technology which was published in the NEJM. Eversince, DreaMed Diabetes has been vigorously working on decision support tools in the diabetes management space and became the first and only company in the world to receive FDA clearance for a decision support system using data from CGM/SMBG and insulin pumps. We offer a clinically proven decision support system for insulin titration in type 1 diabetes patients. Our Advisor Pro software was created by diabetes professionals and is based on real-world experience, turbo-charged by artificial intelligence. Using it, any healthcare professional can analyze patient data in seconds and advise on the optimal treatment plan. By frequent titration changes and online monitoring, we allow patients better treatment thus by lowering their A1C levels and risk for complications. Using the Advisor Pro physicians and nurses can provide true patient-centered care and everyone can receive the same top-level of treatment – wherever they are and whoever their caregiver is.

Total Funding Amount:

$13.3M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Petah Tiqva, HaMerkaz, Israel

Founded Date:

2014-01-01

Contact Email:

info(AT)dreamed.ai

Founders:

Aviel Fogel, Dr. Revital Nimri, Eran Atlas, Ido Muller, Moshe Phillip, Shahar Miller

Number of Employees:

11-50

Last Funding Date:

2024-08-19

IPO Status:

Private

© 2024 MyAiNote.com